'+pages+''); $('.stream > div:odd').addClass('bgr_color'); updateHeight('#history'); }); window.activateTabArea = ensure(function(tab, areas){ var parsed = false; var parts = (areas || '').split('/'); window.fsonload = $.inArray('fs', parts) >= 0; if(fsonload){ parts.splice(parts.indexOf('fs'), 1); } var replayMode = false; if($.inArray('replay', parts)>=0){ replayMode = 'replay'; } var noSoundMode = false; if($.inArray('nosound', parts)>=0){ noSoundMode = 'nosound'; } if($.inArray('ns', parts)>=0){ noSoundMode = 'ns'; } var previewMode = null; if($.inArray('p', parts)>=0){ previewMode = 'p'; } if($.inArray('preview', parts)>=0){ previewMode = 'preview'; } if($.inArray('repeat', parts)>=0){ replayMode = 'repeat'; } if($.inArray('r', parts)>=0 || $.inArray('ro', parts)>=0){ replayMode = 'r'; } if(replayMode){ parts.splice(parts.indexOf(replayMode), 1); } if(noSoundMode){ parts.splice(parts.indexOf(noSoundMode), 1); } if(previewMode){ parts.splice(parts.indexOf(previewMode), 1); } if(previewMode){ if(!parts.length){ parts = ['1-14', '999:59']; } } var area = parts[0]; if(tab == 'history' && false){ var page = parseInt(area || '1') || 1; $.ajax({ url: 'https://login.wn.com/recent/json/?pp='+history_pp+'&skip='+history_pp*(page-1), dataType: 'jsonp', success: function(response){ $ensure(function(){ renderHistory(response, page); }); } }); return true; } if(tab == 'global_history' && false){ var page = parseInt(area || '1') || 1; globalHistory.fetchStream(page, '', function(){ updateHeight('#global_history'); }); return true; } if(tab == 'my_playlists' && false){ var page = parseInt(area || '1') || 1; myPlaylists.fetchStream(page, '', function(){ updateHeight('#my_playlists'); }); return true; } if(tab == 'my_videos' && false){ var page = parseInt(area || '1') || 1; myVideos.fetchStream(page, '', function(){ updateHeight('#my_videos'); }); return true; } if(tab == 'related_sites' && areas && matchPosition(areas)){ var seconds = parsePosition(areas); scrollRelated(seconds); return false; } if(matchPosition(area) || matchAction(area)){ parts.unshift('1'); area = parts[0]; } if(tab == 'expand' && area && area.match(/\d+/)) { var num = parseInt(area); if(num < 100){ //FIX ME. Load news page with ajax here } else if(num > 1900){ //FIX ME. Load timeline page with ajax here } } else if(tab.match(/^playlist\d+$/)){ var playerId = parseInt(tab.substring(8)); var vp = videoplayers[playerId]; window.descriptionsholder = $('.descriptionsplace'); if(!vp) return; // why? no player? if(replayMode){ $('.replaycurrent'+playerId).attr('checked', true); vp.setReplayCurrent(true); } var playQueue = []; window.playQueue = playQueue; var playQueuePosition = 0; var playShouldStart = null; var playShouldStop = null; var parseList = function(x){ var items = x.split(/;|,/g); var results = []; for (i in items){ try{ var action = parseAction(vp, items[i]); if(!action.video){ if(window.console && console.log) console.log("Warning: No video for queued entry: " + items[i]); }else{ results.push(action); } }catch(e){ if(window.console && console.log) console.log("Warning: Can''t parse queue entry: " + items[i]); } } return results; }; var scrollToPlaylistPosition = function(vp){ var ppos = vp.getPlaylistPosition(); var el = vp.playlistContainer.find('>li').eq(ppos); var par = el.closest('.playlist_scrollarea'); par.scrollTop(el.offset().top-par.height()/2); } var updateVolumeState = function(){ if(noSoundMode){ if(noSoundMode == 'turn-on'){ clog("Sound is on, vsid="+vp.vsid); vp.setVolumeUnMute(); noSoundMode = false; }else{ clog("Sound is off, vsid="+vp.vsid); vp.setVolumeMute(); noSoundMode = 'turn-on'; } } } var playQueueUpdate = function(){ var playPosition = playQueue[playQueuePosition]; vp.playFromPlaylist(playPosition.video); scrollToPlaylistPosition(vp); playShouldStart = playPosition.start; playShouldStop = playPosition.stop; }; var playQueueAdvancePosition = function(){ clog("Advancing play position..."); playQueuePosition ++; while(playQueuePosition < playQueue.length && !playQueue[playQueuePosition].video){ playQueuePosition ++; } if(playQueuePosition < playQueue.length){ playQueueUpdate(); }else if(vp.getReplayCurrent()){ playQueuePosition = 0; playQueueUpdate(); vp.seekTo(playShouldStart); vp.playVideo(); }else{ vp.pauseVideo(); playShouldStop = null; playShouldStart = null; } }; function loadMoreVideos(playerId, vp, start, finish, callback){ var playlistInfo = playlists[playerId-1]; if(playlistInfo.loading >= finish) return; playlistInfo.loading = finish; $.ajax({ url: '/api/upge/cheetah-photo-search/query_videos2', dataType: 'json', data: { query: playlistInfo.query, orderby: playlistInfo.orderby, start: start, count: finish-start }, success: function(response){ var pl = vp.getPlaylist().slice(0); pl.push.apply(pl, response); vp.setPlaylist(pl); callback(); } }); } if(parts.length == 1 && matchDash(parts[0])){ var pl = vp.getActualPlaylist(); var vids = parseDash(parts[0]); parts = []; for(var i = 0; i < vids.length; i++){ playQueue.push({ 'video': pl[vids[i]-1], 'start': 0, 'stop': null }) } if(vids.length){ if(vids[vids.length-1]-1>=pl.length){ loadMoreVideos(playerId, vp, pl.length, vids[vids.length-1], function(){ if(fsonload){ activateTabArea(tab, parts[0]+'/fs'); }else{ activateTabArea(tab, parts[0]); } var pls = vp.getPlaylist(); vp.playFromPlaylist(pls[pls.length-1]); vp.playVideo(); scrollToPlaylistPosition(vp); }); return true; } } if(playQueue){ playQueueUpdate(); vp.playVideo(); parsed = true; playShouldStart = 0; } } if(previewMode){ var vids = []; var dur = 0; var pl = vp.getActualPlaylist(); area = parts[0]; if(parts.length == 1 && matchPosition(parts[0])){ vids = parseDash('1-'+pl.length); dur = parsePosition(parts[0]); parts = []; }else if(parts.length == 1 && matchDash(parts[0])){ vids = parseDash(parts[0]); dur = parsePosition("999:59"); parts = []; } if(parts.length == 2 && matchDash(parts[0]) && matchPosition(parts[1])){ vids = parseDash(parts[0]); dur = parsePosition(parts[1]); parts = []; } for(var i = 0; i < vids.length; i++){ playQueue.push({ 'video': pl[vids[i]-1], 'start': 0, 'stop': dur }) } if(playQueue){ playQueueUpdate(); vp.playVideo(); parsed = true; } } if(parts.length>1){ for(var i = 0; i < parts.length; i++){ var sel = findMatchingVideo(vp, parts[i]); if(sel){ playQueue.push({ 'video': sel, 'start': 0, 'stop': null }) } } if(playQueue){ playQueueUpdate(); vp.playVideo(); parsed = true; } }else if(area){ var sel = findMatchingVideo(vp, area); if(sel){ vp.playFromPlaylist(sel); playShouldStart = 0; parsed = true; } } if(fsonload || replayMode){ playShouldStart = 0; } if(document.location.search.match('at=|queue=')){ var opts = document.location.search.replace(/^\?/,'').split(/&/g); for(var o in opts){ if(opts[o].match(/^at=(\d+:)?(\d+:)?\d+$/)){ playShouldStart = parsePosition(opts[o].substr(3)) } if(opts[o].match(/^queue=/)){ playQueue = parseList(opts[o].substr(6)); if(playQueue){ playQueuePosition = 0; playQueueUpdate(); } } } } if(matchPosition(parts[1])){ playShouldStart = parsePosition(parts[1]); parsed = true; } if(matchAction(parts[1])){ var action = parseAction(vp, area+'/'+parts[1]); playShouldStart = action.start; playShouldStop = action.stop; parsed = true; } if(playShouldStart !== null && !playQueue.length){ playQueue.push({ video: vp.getCurrentVideo(), start: playShouldStart, stop: playShouldStop }); } if(playShouldStart != null){ setInterval(function(){ if(playShouldStop && vp.currentPlayer && vp.currentPlayer.getCurrentTime() > playShouldStop){ playShouldStop = null; if(vp.getCurrentVideo() == playQueue[playQueuePosition].video){ playQueueAdvancePosition(); }else{ playShouldStart = null; } } }, 500); vp.playerContainer.bind('videoplayer.player.statechange', function(e, state){ if(state == 'ended'){ // advance to the next video playQueueAdvancePosition(); } }); vp.playerContainer.bind('videoplayer.player.readychange', function(e, state){ if(state){ updateVolumeState(); if(playShouldStart !== null){ vp.seekTo(playShouldStart); playShouldStart = null; }else{ playShouldStop = null; // someone started other video, stop playing from playQueue } } if(fsonload) { triggerFullscreen(playerId); fsonload = false; } }); } } else if(tab.match(/^wiki\d+$/)){ if(firstTimeActivate){ load_wiki($('#'+tab), function(){ if(area){ var areaNode = $('#'+area); if(areaNode.length>0){ $('html, body').scrollTop(areaNode.offset().top + 10); return true; } } }); } } return parsed; }) window.activateTab = ensure(function(tab, area){ window.activeArea = null; if(tab == 'import_videos'){ if(area){ import_videos(area); }else{ start_import(); } return true; } if(tab == 'chat'){ update_chat_position($('.chat').eq(0)); window.activeArea = 'chat'; jQuery('.tabtrigger').offscreentabs('activateTab', 'chat'); return true; } if(tab in rev_names){ tab = rev_names[tab]; } if(tab.match(':')){ return false; } var sup = $('ul li a[id=#'+tab+']'); if(sup && sup.length>0){ window.activeArea = area; sup.first().click(); if(!window.activateTabArea(tab, area)){ window.activeArea = null; } window.activeArea = null; return true; }else{ var have_tabs = $('#playlist_menu li').length; if(tab.match(/^playlists?\d+$/)){ var to_add = +tab.substring(8).replace(/^s/,'')-have_tabs; if(to_add>0 && have_tabs){ add_more_videos(to_add); return true; } } } return false; }); window.currentPath = ensure(function(){ return window.lastHistory.replace(basepath, '').split('?')[0]; }); window.main_tab = window.main_tab || 'videos'; window.addHistory = ensure(function(path){ if(window.console && console.log) console.log("Adding to history: "+path); if(window.history && history.replaceState && document.location.hostname.match(/^(youtube\.)?(\w{2,3}\.)?wn\.com$/)){ if(path == main_tab || path == main_tab+'/' || path == '' || path == '/') { path = basepath; } else if( path.match('^'+main_tab+'/') ){ path = basepath + '/' + path.replace(main_tab+'/', '').replace('--','/'); } else { path = basepath + '/' + path.replace('--','/'); } if(document.location.search){ path += document.location.search; } if(window.lastHistory) { history.pushState(null, null, path); } else if(window.lastHistory != path){ history.replaceState(null, null, path); window.lastHistory = path; } } else{ path = path.replace('--','/'); if(path == main_tab || path == main_tab+'/' || path == '' || path == '/') { path = ''; } if(window.lastHistory != '/'+path){ window.location.hash = path? '/'+path : ''; window.lastHistory = '/'+path; } } }); $('.tabtrigger li a').live('click', ensure(function() { var tab = $(this).attr('id'); if(tab.substring(0,1) == '#'){ var name = tab.substring(1); if(name in menu_names){ name = menu_names[name][0]; } realTab = rev_names[name]; $('#'+realTab).show(); if(window.console && console.log) console.log("Triggering tab: "+name+(window.activeArea?" activeArea="+window.activeArea:'')); var path = name; if(window.activeArea){ path = path + '/' + window.activeArea; } if(tab.match(/#playlist\d+/) || tab.match(/#details\d+/)){ $('.multiple-playlists').show(); $('.related_playlist').show(); $('.longest_videos_playlist').show(); }else { $('.multiple-playlists').hide(); $('.related_playlist').hide(); $('.longest_videos_playlist').hide(); } // start the related script only when the tab is on screen showing if (tab.match(/related_sites/)) { if (mc) { mc.startCredits(); } } window.activeTab = realTab; addHistory(path); setTimeout(ensure(function(){ if(tab.match(/language--/)){ $('.tabtrigger').offscreentabs('activateTab', 'language'); } if(tab.match(/weather/)) { $('.tabtrigger').offscreentabs('activateTab', 'weather'); loadContinent(); } updateMenus(tab); updateHeight(); }), 10); } return false; })); }); -->

'); } else { var query = elem.find('.keywords').html(); $.ajax({ context: elem, url: 'https://wn.com/api/upge/cheetah-search-adv/video', cache: true, data: { 'query': query }, dataType: 'jsonp', success: function(text) { if (text.length > 0) { video_id = text[0].id; elem.find('.player').html(''); } } }); } } var stopAllYouTubeVideos = function() { var iframes = document.querySelectorAll('iframe'); Array.prototype.forEach.call(iframes, function(iframe) { iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*'); }); } jQuery(function() { jQuery(".playVideo").live("click", function() { if(!$(this).hasClass("played")){ stopAllYouTubeVideos(); var elem = $(this); setTimeout(function(){ mouseOverMe(elem); }, 1000); } }); jQuery(".description_box .expandContent").live("click", function() { elem = $(this).parent().parent().parent().find('.descContent'); if(elem.height() > 51) { elem.css('height', '44px'); $(this).html('Show More '); }else{ elem.css('height', 'auto'); $(this).html('Hide '); } }); jQuery('.interview-play-off').click(function() { $(".interview-play-off").hide(); $(".interview-play").show(); $(".videoplayer-control-pause").click(); }); jQuery(".video-desc .show_author_videos").live("click", function() { query = $(this).attr('title'); container = $(this).parent().parent().parent().find('.video-author-thumbs'); $(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px'); jQuery.ajax({ url: '/api/upge/cheetah-photo-search/videoresults', data: {'query': query}, success: function(text) { if(!text) { text = i18n("No results"); } container.html(jQuery(text)); } }); }); }); // -->

Latest News for: bcl xl

Edit

LOMOND THERAPEUTICS REPORTS RESULTS FROM ONGOING CLINICAL STUDIES OF LONITOCLAX, A SELECTIVE BCL-2 INHIBITOR WITH BEST-IN-CLASS SELECTIVITY VERSUS BCL-XL AND NO CYP 3A4 LIABILITY

PR Newswire 09 Dec 2024
To mitigate the hematologic and immune toxicities observed with venetoclax, lonitoclax was designed with a unique binding mode to improve selectivity for Bcl-2 over Bcl-xL.
Edit

Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

GetNews 30 Oct 2024
Amgen ... APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process ... Email.
Edit

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of ...

Invezz 14 Sep 2024
ROCKVILLE, Md ... Prof ... Dr ... The company has built a rich pipeline of innovative drug candidates that includes novel, highly potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs.
Edit

Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by ...

The Manila Times 13 Aug 2024
The company has built a pipeline of 9 clinical-stage drug candidates, including novel, highly potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs.
Edit

Small Cell Lung Cancer Pipeline 2024 | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E ...

GetNews 09 Jul 2024
Amgen ... APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process ... Email.
Edit

Olverembatinib Approved for Commercialization in Macau China

The Manila Times 08 Jul 2024
ROCKVILLE, Md ... Reference. ... ... The company has built a pipeline of 9 clinical-stage drug candidates, including novel, highly potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs.
Edit

Ascentage Pharma Received US$100 Million Option Payment from Takeda

The Manila Times 04 Jul 2024
ROCKVILLE, Md ... Ascentage Pharma has built a pipeline of 9 clinical-stage drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs ... ....
Edit

Myelofibrosis Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Options, Therapies, Key Companies | ...

GetNews 17 Jun 2024
Emerging treatments are exploring diverse mechanisms beyond JAK inhibitors, such as imetelstat (a telomerase inhibitor), navitoclax (an inhibitor of BCL-XL/BCL-2), GB2064 (inhibitors of LOXL2 ...
Edit

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for ...

The Manila Times 16 May 2024
The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).
Edit

Small Cell Lung Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and ...

GetNews 13 May 2024
AMG 757. Amgen ... APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process.
Edit

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of ...

The Eagle-Tribune 06 Mar 2024
The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs) ... .
Edit

Hypoglycemic Functional Factors in Natural Products and Their Mechanisms of Action

Pharmiweb 20 Feb 2024
Plant saponins like ginsenosides can alleviate insulin resistance by activating the IRS1/PI3K/AKT/GSK3β-GS signaling pathway, regulating blood glucose levels by lowering the Bax/Bcl-xL ratio, JNK phosphorylation levels, and Caspase-3 activity ... .
Edit

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide ...

Enid News & Eagle 06 Feb 2024
Researchers showed that senolysis through BCL-xL inhibition improved retinal barrier function in diabetic mice, modifying the retinal microenvironment and reestablishing tissue homeostasis ... The BCL-xL ...
Edit

Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive ...

The Eagle-Tribune 17 Jan 2024
... The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs) ... .
Edit

Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference

The Eagle-Tribune 02 Jan 2024
... The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Most Viewed

×